A Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effects on Heterotopic Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

Trial Profile

A Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effects on Heterotopic Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs REGN 2477 (Primary)
  • Indications Fibrodysplasia ossificans progressiva
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LUMINA-1
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 16 Nov 2017 Planned End Date changed from 9 Apr 2020 to 14 May 2020.
    • 16 Nov 2017 Planned primary completion date changed from 9 May 2019 to 12 Jun 2019.
    • 16 Nov 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top